Skip to content
Lower risk Drug recall · FDA · Published July 21, 2022

Teva Matzim LA 240mg Tablets Recall: Failed Dissolution Specifications

Teva Pharmaceuticals recalls Matzim LA 240mg extended-release tablets due to failed dissolution specifications. This may affect medication effectiveness. Check your product details to see if you need to take action.

🇺🇸 FDA recall #D-1303-2022DrugTeva Pharmaceuticals ›
Take action

Contact the company

Recalling firmTeva Pharmaceuticals USA Inc400 Interpace Pkwy Bldg A · Parsippany, NJ 07054-1120
✎ GovInfoNow plain-language explainer

Teva Pharmaceuticals is recalling Matzim LA (Diltiazem Hydrochloride) 240mg extended-release tablets because they may not dissolve properly as intended. This could lead to inconsistent medication levels in the body, potentially affecting treatment effectiveness. Read more at govinfonow.com/recall/34396-teva-matzim-la-240mg-tablets-recall-failed-dissolution-specifications.

Source Summary by GovInfoNow · govinfonow.com/recall/34396-teva-matzim-la-240mg-tablets-recall-failed-dissolution-specifications · Updated August 18, 2026 · FDA enforcement record: FDA #D-1303-2022

Cite this page

“Teva Matzim LA 240mg Tablets Recall: Failed Dissolution Specifications.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34396-teva-matzim-la-240mg-tablets-recall-failed-dissolution-specifications. Based on FDA recall #D-1303-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1303-2022%22&limit=1).

The FDA announced on July 21, 2022, that Teva Pharmaceuticals USA Inc. is recalling Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets due to failed dissolution specifications. The agency stated the recall was voluntary and initiated by the firm.

How to tell if you have it

  • Brand: Teva Pharmaceuticals
  • Product: Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg
  • Packaging: 30-count bottles, Rx Only
  • NDC: 58544-692-30
  • Lot Code: 1411596A
  • Expiration Date: 09/22
  • Quantity: 5677 bottles

The hazard

The recall addresses failed dissolution specifications, where the product fell below specification limits for dissolution. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show Teva Pharmaceuticals USA, Inc. has 59 other recalls on record since April 2, 2012. Other recent recalls of similar products include Teva recalling traZODone 50mg tablets with foreign tablets risk (Aug. 24, 2026) and Teva Octreotide Acetate 30mg Kit due to sterility risk (April 24, 2026). Other recent recalls of similar products include Inventia Chlorthalidone Recall for failed dissolution specs (Sept. 3, 2026) and Novartis Recalls Diovan 160mg Tablets due to failed dissolution specifications (Aug. 4, 2026).

How to tell if you have this one

Check for the product name Matzim LA, 240mg, 30-count bottles, Rx Only. The lot number 1411596A and expiration date 09/22 are specific identifiers for this recall.

  • Brand
    Teva Pharmaceuticals
  • Category
    Drug
FDA recall event · 2 products

All 2 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Terminated
  • Distribution
    Nationwide in the USA and Puerto Rico
Recall numberProduct, codes & lotsQuantityNDC
D-1302-2022Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA; NDC 52544-691-30.; Lot 1411593A, Exp 09/228022 bottles52544-691-30, 52544-691-19, 52544-691-10, 52544-692-30, 52544-692-19, 52544-692-10, 52544-693-30, 52544-693-19, 52544-693-10, 52544-694-30, 52544-694-19, 52544-694-10, 52544-695-30, 52544-695-19, 52544-695-10
D-1303-2022Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.; Lot 1411596A, Exp 09/225677 bottles—
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Look for the product name Matzim LA, 240mg, 30-count bottles, Rx Only with lot number 1411596A and expiration date 09/22.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide in the USA and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 9 months after the firm started it.

1. Firm started the recall: Jul 21, 202212. FDA classified it Class II: Aug 4, 202223. Published in FDA’s Enforcement Report: Aug 10, 202234. FDA terminated the recall: Apr 18, 2023420222023
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Is this recall dangerous?

The recall is for medication that may not dissolve properly, which could affect treatment effectiveness. However, it does not pose an immediate risk of serious injury.

Similar recalls

Other Teva Pharmaceuticals recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1303-2022 (July 21, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1303-2022 to see it in context.
  • Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA